as of 12-05-2025 3:43pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 186.7M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $5.20 | Next Earning Date: | 11-12-2025 |
| Revenue: | $34,419,000 | Revenue Growth: | -24.52% |
| Revenue Growth (this year): | -6.09% | Revenue Growth (next year): | 10.69% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
AI Sentiment
Highly Positive
9/10
AI Sentiment
Positive
7/10
AI Sentiment
Positive
7/10
See how MXCT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.